About Jacqueline Shea

Dr. Jacqueline Shea has served as INOVIO’s President and Chief Executive Officer (CEO) since May 2022. She is responsible for determining and leading INOVIO’s overall corporate strategy across its clinical programs and advancing its DNA medicines platform to support unmet medical needs and global public health.

Dr. Shea joined the Company in March 2019 as Chief Operating Officer (COO), serving as a key member of the executive team. She led INOVIO’s manufacturing, commercial, business development, project and alliance management operations..

Dr. Shea has more than 25 years’ experience in the life sciences and biotech industries. Prior to joining INOVIO, she was previously the COO and later the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB). During her tenure she oversaw two major clinical trial breakthroughs in the development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium.

A molecular biologist and cell cycle geneticist by training, Dr. Shea has dedicated much of her career to developing innovative products to prevent and treat infectious diseases. She has been named as an inventor on more than 20 patents, is an author of numerous scientific publications, has served on multiple advisory boards and currently serves on the Board of Trustees for the Sabin Vaccine Institute. Dr. Shea received a BSc in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.